Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
J Control Release. 2017 Aug 28;260:46-60. doi: 10.1016/j.jconrel.2017.05.028. Epub 2017 May 20.
The lack of efficient therapeutic options for many severe disorders including cancer spurs demand for improved drug delivery technologies. Nanoscale drug delivery systems based on poly(ethylene glycol)-poly(ε-caprolactone) copolymers (PEG-PCL) represent a strategy to implement therapies with enhanced drug accumulation at the site of action and decreased off-target effects. In this review, we discuss state-of-the-art nanomedicines based on PEG-PCL that have been investigated in a preclinical setting. We summarize the various synthesis routes and different preparation methods used for the production of PEG-PCL nanoparticles. Additionally, we review physico-chemical properties including biodegradability, biocompatibility, and drug loading. Finally, we highlight recent therapeutic applications investigated in vitro and in vivo using advanced systems such as triggered release, multi-component therapies, theranostics, or gene delivery systems.
许多严重疾病（包括癌症）缺乏有效的治疗方法，这促使人们对改进的药物输送技术产生了需求。基于聚乙二醇-聚（ε-己内酯）共聚物（PEG-PCL）的纳米级药物输送系统是一种在作用部位增强药物积累并减少脱靶效应的策略。在这篇综述中，我们讨论了在临床前研究中已经研究过的基于 PEG-PCL 的最先进的纳米药物。我们总结了用于制备 PEG-PCL 纳米粒子的各种合成路线和不同的制备方法。此外，我们还综述了物理化学性质，包括生物降解性、生物相容性和药物负载。最后，我们强调了最近使用先进系统（如触发释放、多组分治疗、治疗学或基因传递系统）在体外和体内进行的治疗应用。
